Hussain M - Search Results

1

Aspirin may do wonders by the induction of immunological self-tolerance against autoimmune atherosclerosis.

Hussain M, Javeed A, Ashraf M, Riaz A, Mushtaq MH. Hussain M, et al. Med Hypotheses. 2012 Jan;78(1):171-3. doi: 10.1016/j.mehy.2011.10.019. Epub 2011 Nov 8. Med Hypotheses. 2012. PMID: 22070887

2

Aspirin and immune system.

Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM, Rehman MU. Hussain M, et al. Int Immunopharmacol. 2012 Jan;12(1):10-20. doi: 10.1016/j.intimp.2011.11.021. Epub 2011 Dec 13. Int Immunopharmacol. 2012. PMID: 22172645 Review.

3

Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy.

Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar MM. Hussain M, et al. Pharmacol Res. 2012 Jul;66(1):7-18. doi: 10.1016/j.phrs.2012.02.003. Epub 2012 Feb 21. Pharmacol Res. 2012. PMID: 22449788 Review.

4

Artemisinins and immune system.

Shakir L, Hussain M, Javeed A, Ashraf M, Riaz A. Shakir L, et al. Among authors: hussain m. Eur J Pharmacol. 2011 Oct 1;668(1-2):6-14. doi: 10.1016/j.ejphar.2011.06.044. Epub 2011 Jul 7. Eur J Pharmacol. 2011. PMID: 21756901 Review.

5

Multilevel pharmacological manipulation of adenosine-prostaglandin E₂/cAMP nexus in the tumor microenvironment: a 'two hit' therapeutic opportunity.

Hussain M, Javeed A, Ashraf M, Yuzhu H, Mukhtar MM. Hussain M, et al. Pharmacol Res. 2013 Jul;73:8-19. doi: 10.1016/j.phrs.2013.04.006. Epub 2013 Apr 22. Pharmacol Res. 2013. PMID: 23619528 Review.

6

Dichotomous role of protein kinase A type I (PKAI) in the tumor microenvironment: a potential target for 'two-in-one' cancer chemoimmunotherapeutics.

Hussain M, Tang F, Liu J, Zhang J, Javeed A. Hussain M, et al. Cancer Lett. 2015 Dec 1;369(1):9-19. doi: 10.1016/j.canlet.2015.07.047. Epub 2015 Aug 11. Cancer Lett. 2015. PMID: 26276720 Review.

7

Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy.

Hussain M, Shah Z, Abbas N, Javeed A, Mukhtar MM, Zhang J. Hussain M, et al. Med Hypotheses. 2016 Jan;86:56-9. doi: 10.1016/j.mehy.2015.11.031. Epub 2015 Dec 11. Med Hypotheses. 2016. PMID: 26804598

8

Exploration of potential ligands against cancer-causing transcription factor E2F3.

Hussain M, Javeed A, Ashraf M, Siddique S, Riaz A, Mukhtar MM. Hussain M, et al. Pak J Pharm Sci. 2012 Oct;25(4):793-801. Pak J Pharm Sci. 2012. PMID: 23009996

9

Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.

Adah D, Hussain M, Qin L, Qin L, Zhang J, Chen X. Adah D, et al. Among authors: hussain m. Pharmacol Res. 2016 Aug;110:25-34. doi: 10.1016/j.phrs.2016.05.007. Epub 2016 May 6. Pharmacol Res. 2016. PMID: 27157248 Review.

10

Efficacy and Safety of Polatuzumab-Vedotin plus Bendamustine and Rituximab in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Systematic Review and Meta-Analysis.

Farooqi HA, Ullah MS, Raza A, Sadiq Z, Shaikh WA, Muhammad R, Hussain MS. Farooqi HA, et al. Among authors: hussain ms. Crit Rev Oncol Hematol. 2025 Jan 8:104611. doi: 10.1016/j.critrevonc.2024.104611. Online ahead of print. Crit Rev Oncol Hematol. 2025. PMID: 39793679 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,514 results

Search Page

Filters